Top Biotech Companies to Watch

Biotechnology is changing at record speed and it’s no surprise that Artificial Intelligence (AI) and Machine Learning (ML) are at the forefront; these tools are shortening drug discovery timelines that previously took decades. And a wave of well-funded, scientifically audacious startups is taking on diseases that medicine has long struggled to treat, from autoimmune conditions and rare genetic disorders to obesity, cancer and neurodegeneration.

What’s Influencing Biotech Innovations?

We are in a very promising moment for biotech for a number of reasons. AI and machine learning have transformed what’s possible in early-stage drug discovery for example. New AI platforms are able to model protein structures, predict interactions and create new molecular candidates resulting in preclinical studies that would have traditionally taken years to complete, now can be done in a matter of months. Additionally, the speed with which the industry was able to pivot to develop and distribute mRNA vaccines during the pandemic proved to everyone how quickly biologic platforms can be developed and distributed. Due to this technological advance, we have seen an increase in investment across the board.

How New Technology is Keeping up With Ambition

But most importantly, the science has caught up to the potential. Cell therapies, RNA therapeutics, gene editing and antibody-drug conjugates are no longer ambitious speculative technologies. They are now delivering clinical efficacy, receiving regulatory approvals and ultimately reaching the patients. Companies that are working with these platforms have a foundation to build upon that simply didn’t exist a decade ago.

Top Biotech Companies to Watch

From AI-driven drug discovery and machine learning to advances in cell and gene therapy, the following innovative companies are working to improve healthcare outcomes across areas like cancer, rare diseases, obesity or autoimmune disease and are worth keeping an eye on into the future:

Insilico Medicine

Insilico Medicine has its headquarters in Boston and is considered one of the leading companies in the development of AI and drug discovery. It has over a decade of experience in using generative AI to develop new drug molecules. This process and technology has continued to receive refinements and improvements throughout the years. As of June 2025, Insilico developed and launched Nach01, amultimodal foundation model.

Iktos

Iktos maintains the development of one of the most advanced AI-assisted molecular design tools in the industry. Iktos’ technology is ran through SaaS software, such as Makya. Their technology focuses on AI molecular design and robotic synthesis, ensuring partners reach from computational estimating to real physical compounds in a shorter timeframe than the industry standard. In July 2024, Iktos acquired Synsight, enhancing its Chemistry AI platform with an innovative biology platform focused on discovering drugs targeting Protein-Protein (PPI) and RNA-Protein (RPI) interactions.

Corsera Health

Only launched in 2025, Corsera Health is led by an exceptional founding team, including former Alnylam CEO John Maraganore and Metsera founder Clive Meanwell; whose last company was sold to Novartis for $9.7 billion. Corsera Health is leveraging AI and RNA interference to treat cardiovascular disease. The company combines an AI-based predictive model estimating cardiovascular risk with a clinical RNAi initiative aimed at damage pre-emption. This is a very ambitious project with a very experienced team, so they are definitely one to watch.

Stylus Medicine

Cell therapy has faced a difficult period, as multiple Big Pharma companies exited the space in 2025, citing manufacturing complexity and commercial challenges. Stylus Medicine launched in May 2025 with a proposition designed to address exactly those problems. The company aims to pioneer next-generation genetic medicines, beginning with CAR-T therapies. They differentiate themselves by by manufacturing an innovative, flexible and durable CAR-T therapy delivered in vivo (inside the body), rather than the more commonly used ex vivo (outside the body) approach.

Treeline Biosciences

Treeline Biosciences is one of the most well-funded private oncology biotechs and has raised an impressive $1.1 billion to fund a precision oncology approach in an aggressive manner. Rather than proceeding in a more typical stepwise fashion with sequencing programs, the firm initiated all three of its Phase 1 clinical trials in 2025, including TLN-121 (a BCL6 degrader) and TLN-254 (an EZH2 inhibitor) and TLN-372 (a pan-KRAS inhibitor). Josh Bilenker, an entrepreneur with experience in successfully guiding Loxo Oncology through the development of multiple FDA-approved cancer drugs prior to its $8 billion acquisition by Eli Lilly, leads the company; making Treeline Biosciences a company to keep up with in the following years.